Over the past 30 years, the genetic sequencing revolution has transformed how ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) are diagnosed, and it is set to change how they are treated.

Professor Matthew Harms explains that almost 20 genes have now been reported to cause an FTD-like phenotype and close to 50 in ALS. Genetic testing yields an answer in about 20% of people with FTD and 15% with ALS, including around 1 in 10 people with no family history of either disease. Beyond confirming the diagnosis and informing families about future risk, testing is becoming a treatment concept. One therapy is already approved for SOD1-related ALS, and gene-targeted therapies that silence or boost gene expression are in clinical trials for both disorders.

Portrait photo of Matthew Harms

Prof. Matthew Harms, MD

Professor of Neurology, Columbia University, USA

Related content

image Image Clinical spectrum of MND-FTD
The MND-FTD clinical spectrum

Motor neuron disease (MND) and frontotemporal dementia (FTD) were once seen as separate conditions, one affecting movement and the other cognition and behaviour. Growing evidence now places them on the same disease spectrum, linked by shared clinical features, genetic causes, and underlying pathology.

17.11.2026 ALS-FTD
grid_view Slide Deck
ALS-FTD spectrum – History, Definitions and Diagnosis

ALS and FTD were historically regarded as distinct diseases but are now recognised as overlapping disorders within a broader neurodegenerative spectrum. This slide deck introduces their defining clinical features, the development of the ALS–FTD concept, and the approaches used to diagnose ALS, FTD and mixed presentations.

17.11.2026 ALS-FTD
image Image Microscopy images showing skein-like and compact protein inclusions in the cytoplasm of degenerating motor neurons.
Protein inclusions in the cytoplasm of degenerating motor neurons

Motor neuron degeneration in ALS is associated with abnormal protein aggregation, including characteristic skein-like and compact cytoplasmic inclusions.

17.11.2026 ALS-FTD